Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grafix (CHAM) for Chronic Diabetic Foot Ulcers
NCT02571738Phase 3Terminated
- Sponsor
- Osiris Therapeutics, Inc.
- Start
- Oct 2015
- Primary completion
- Apr 2017
- Modality
- Tissue Cells, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of human amniotic membrane allograft in diabetic foot ulcer (DFU) (2 arms), sponsored by Osiris Therapeutics, Inc. Primary endpoint: Complete closure of the index wound at 112 days. Started Oct 2015; status: terminated.
02
Drugs
human amniotic membrane allograft
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02571738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571738.